Arexvy, a respiratory syncytial virus (RSV) vaccine, is a brand-name intramuscular injection. It’s prescribed to help prevent lower respiratory infections from RSV. Arexvy has no known ...

On Wednesday, the US Food and Drug Administration approved Arexvy, made by GSK, which is designed to be given as a single shot to adults 60 and older.

GSK announced that Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) is now available in the United States at all major retail pharmacies. In June, the Advisory Committee on Immunization ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a Phase 3 trial. Read more here.

Among participants who received a second dose of Arexvy, cumulative vaccine efficacy over 2 seasons was 67.1% (97.5% CI, 48.1-80.0), with 30 cases in the vaccine arm vs 139 cases in the placebo arm.

AREXVY is indicated for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older, as well as individuals 50 through 59 years of age who are ...

In May, the U.K. company was first to secure FDA approval for its shot Arexvy for adults 60 and older, beating out rivals from Pfizer and Moderna.

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

The safety and immunogenicity of Arexvy in adults aged 18 to 49 years at increased risk of RSV disease (n=395) was compared with adults aged 60 and older (n=417) in a phase 3b open-label trial ...

The sales for Arexvy were reported at approximately £709M ($865.98M), a figure that outpaced analysts' expectations which were pegged at £358M.